Replies to post #3347 on Ayala Pharmaceuticals Inc (ADXS)

[terry hallinan]

Morning, James.

Compared to other historical treatment regimes. 50 % survival would be very significant, and remember this is just with 3 doses of the vaccine.

I have no argument at all with the excellence of the published results and promise of the future but they won't likely be good enough to lead directly to approval like another ADXS vaccine:

Aratana received communication from the USDA in March 2015 that the efficacy data previously submitted for product license for AT-014, the cancer vaccine for canine osteosarcoma, licensed from Advaxis, Inc. was accepted to provide a reasonable expectation of efficacy to support conditional licensure. While the Company needs to complete additional steps, including in the areas of manufacturing and safety, Aratana anticipates that AT-014 could receive conditional licensure from the USDA in 2016.

http://finance.yahoo.com/news/aratana-therapeutics-reports-fourth-quarter-220600799.html

In a research hospital where I met my wife so long ago, a doctor told me they were going to cure a cancer that was certain death at the time.

Yeah, sure you are.

But he was good to his word.

Since that time, a girl in our neighborhood survived her juvenile leukemia, has grown children of her own and all have melted into the crowds. Most cases are cured today though that "cure" word remains verboten.

I expect ADXS to do much better but it is only a wan hope for now rather than any sort of guarantee.

Best, Terry